217196-31-1

Upstream product

• 452-08-4 2-bromo-4-fluoro-1-methoxybenzene 
• 71313-97-8 2-(5-fluoro-2-methoxyphenyl)propan-2-ol 
• 459-60-9 1-fluoro-4-methoxybenzene 
• 851314-92-6 2-(2-chloro-1,1-dimethylethyl)-4-fluoro-1-methoxybenzene 
• 566920-34-1 4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-oxopentanoic acid ethyl ester 
• 876587-31-4 (S)-2-{2-[5-fluoro-2-(methyloxy)phenyl]-2-methylpropyl}-2-(trifluoromethyl)oxirane 
• 95-92-1 oxalic acid diethyl ester 

Downstream Products

• 851314-93-7 4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-oxopentanoic acid (1R,2S)-2-phenylcyclohexyl ester 
• 566920-54-5 2-cyclohexylmethyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)amide 
• 566920-43-2 2-cyclohexylmethyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide 
• 566920-89-6 2-(3,5-dimethylbenzyl)-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide 
• 566920-55-6 4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(2-methylbenzyl)pentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide 
• 566920-52-3 2-benzyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (4-methyl-1-oxo-1H-benzo[d][1,2]oxazin-6-yl)amide 
• 566920-85-2 4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-(3-methylbenzyl)pentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide 
• 217195-22-7 6-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-valeroylamino]-4-methyl-2,3-benzoxazin-1-one 
• 566920-36-3 2-benzyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentanoic acid (1-oxo-1,3-dihydroisobenzofuran-5-yl)amide 
• 271587-28-1 5-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-valeroylamino]-phthalide 
• 217193-92-5 5-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethyl-valeroylamino]-phthalide 
• 217197-00-7 6-[4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-oxo-valeroylamino)-4-methyl-2,3-benzoxazin-1-one 
• 934391-82-9 4-(5-fluoro-2-methoxy-phenyl)-4-methyl-2-oxo-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide 
• 851314-94-8 (αR)-5-fluoro-2-methoxy-γ,γ-dimethyl-α-(trifluoromethyl)-α-[(trimethylsilyl)oxy]-benzenebutanoic acid (1R,2S)-2-phenylcyclohexyl ester 

Relevant academic research and scientific papers

Practical stereoselective synthesis of an α-trifluoromethyl-α- alkyl epoxide via a diastereoselective trifluoromethylation reaction

A practical stereoselective synthesis is reported for an α-trifluoromethyl-α-alkyl epoxide (1), which is an important pharmaceutical intermediate. The key step involves a chiral auxiliary-controlled asymmetric trifluoromethylation reaction for the introdu

STEREOSELECTIVE SYNTHESIS OF CERTAIN TRIFLUOROMETHYL-SUBSTITUTED ALCOHOLS

A process for stereoselective synthesis of compounds of Formula (X) wherein: R1 is an aryl or heteroaryl group, each optionally independently substituted with one to three substituent groups, wherein each substituent group of R1 is i

Trifluoromethyl group as a pharmacophore: Effect of replacing a CF 3 group on binding and agonist activity of a glucocorticoid receptor ligand

Compound 1, a potent glucocorticoid receptor ligand, contains a quaternary carbon bearing trifluoromethyl and hydroxyl groups. This paper describes the effect of replacing the trifluoromethyl group on binding and agonist activity of the GR ligand 1. The r

Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof

A compound of Formula (I) wherein R1, R2, R3, R4, R5, and R6 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds,

Nonsteroidal gestagens

This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2and R3have the meanings that are indicated in more detail in the description. The new compounds show a very great affin

Nonsteroidal gestagens

This invention describes the new, nonsteroidal gestagens of general formula I in which A, B, Ar, R1, R2and R3have the meanings that are indicated in more detail in the description. The new compounds show a very great affinity to the gestagen receptor. They can be used alone or in combination with estrogens in contraceptive preparations. In addition, they can be used for treating endometriosis. Together with estrogens, they can also be used in preparations for treating gynecological disorders, for treating premenstrual symptoms and for substitution therapy. Based on the androgenic action, they can also be used for male birth control, male HRT and hormone therapy and for treating andrological disease agents.